458 | OPTIMIZING POST–CHIMERIC ANTIGEN RECEPTOR T CELL MONITORING: EVIDENCE ACROSS LISOCABTAGENE MARALEUCEL PIVOTAL CLINICAL TRIALS AND REAL‐WORLD EXPERIENCE
M. Kamdar(University of Colorado Cancer Center), Matthew A. Lunning(University of Nebraska Medical Center), M. Shadman(University of Washington), Alberto Vasconcelos(Bristol-Myers Squibb (Switzerland)), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Daniela Bernasconi(Bristol-Myers Squibb (Switzerland)), Alessandro Crotta(European Organisation for Rare Diseases), Iris Isufi(Yale University), Bradley D. Hunter(Intermountain Healthcare), David B. Miklos(Stanford University), Marcelo C. Pasquini(Cleveland Clinic), Eric Bleickardt(Unknown), Jennifer L. Crombie(Dana-Farber Cancer Institute), Nausheen Ahmed(Health Care Foundation of Greater Kansas City), Miguel-Angel Perales(Memorial Sloan Kettering Cancer Center), Debasmita Roy(Bristol-Myers Squibb (United States)), Jeremy S. Abramson(Massachusetts General Hospital), M. Frigault(Massachusetts General Hospital), Abu‐Sayeef Mirza(University of South Florida)
Cited by 0
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560